Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer

PierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, Eleftherios P Mamounas, Gunter von Minckwitz, Max S Mano, Michael Untch, Chiun-Sheng Huang, Norman Wolmark, Priya Rastogi, Veronique D'Hondt, Andrés Redondo, Ljiljana Stamatovic, Hervé Bonnefoi, Hugo Castro-Salguero, Hans H Fischer, Tanya Wahl, Chunyan Song, Thomas Boulet, Peter TraskCharles E Geyer

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences